Vinorelbine for HER2-Positive Breast Cancer After Trastuzumab
Author Information
Author(s): Montemurro Filippo, Redana Stefania, Nolè Franco, Donadio Michela, Jacomuzzzi Maria Elena, Valabrega Giorgio, Viale Giuseppe, Sapino Anna, Aglietta Massimo
Primary Institution: Divisione di Oncologia Medica, AO Ordine Mauriziano/Istituto per la Ricerca e la Cura del Cancro, Candiolo, Torino, Italy
Hypothesis
Vinorelbine-based salvage therapy is effective for HER2-positive metastatic breast cancer patients who progress during trastuzumab treatment.
Conclusion
Vinorelbine-based combinations are active and should be further evaluated in trastuzumab-resistant patients.
Supporting Evidence
- The overall response rate was 28% in evaluable patients.
- The clinical benefit rate was 50% for patients with stable disease lasting at least 6 months.
- Median time to progression was 7.1 months.
- Median overall survival was 21 months.
Takeaway
This study shows that vinorelbine can help women with a specific type of breast cancer when other treatments stop working.
Methodology
Retrospective analysis of 424 women with HER2-positive breast cancer receiving trastuzumab-based therapy.
Potential Biases
Potential biases due to non-uniform assessment of disease progression and treatment response.
Limitations
The study is retrospective and lacks centralized review of tumor responses.
Participant Demographics
Median age was 55 years, with most patients having visceral involvement and some with central nervous system metastases.
Statistical Information
P-Value
0.13
Confidence Interval
95% C.I. 18%-41%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website